Long established as a cornerstone of care is lung cancer management that is tailored for age, comorbidities, cancer type, cancer stage, and patient desire. Emerging biologic treatments, immunotherapies, and targeted medicines for non-small-cell lung cancer made possible by advancements in genetics and molecular science are new to this field of personalized management. Based on the distinct molecular properties of a particular patient and the particular malignancy, these techniques have given rise to a new discipline called precision medicine. The most popular care options for stage I through stage III lung cancers continue to be standard management, which includes surgery, chemotherapy, and radiation therapy. Patients with stage IV (i.e., metastatic) lung malignancies stand to benefit the most from advances in precision medicine. The two main components of preoperative evaluation are functional patient assessment and pulmonary function tests. In patients who can withstand surgery, early palliative care and a minimally invasive technique should be taken into account.